Skip to Main Content
Contribute Try STAT+ Today

The pharmaceutical industry says that if the U.S. reduces the astronomical drug prices paid by U.S. consumers, lifesaving innovation will be devastated.

That’s not true. There are ways for the U.S. to reduce drug prices while maintaining and perhaps even accelerating its innovation engine.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Everyone agrees that drug prices particularly price increases are not sustainable. But another phony “expert” with no expertise in drug development spouting off is not helpful. The mRNA vaccines were built upon basic research- but the idea that Universities and the NIH can seamlessly replace drug companies is laughable to anyone with any experience in drug development. Funding more NIH grants will not magically result in more treatments if drug companies are eliminated- universities have minimal expertise in many areas particularly scaling manufacturing in a tightly controlled manner.

    • I don’t agree with your first sentence — drug costs have been around 12-14% of total healthcare costs for years. And during that time we are getting more and more for drugs for that price (as new drugs are added and old ones go generic). How is that unsustainable?

      Healthcare is a labor intensive business, but it is much easier politically to complain about pharma profits than to look at salaries for doctors, nurses, hospital administrators, technicians etc.

Comments are closed.